Monoclonal antibody treatments help with COVID-19, but not without a cost

<p>On the COVID-19 front, monoclonal antibody treatments have increased in both supply and demand, but there are plenty of costs to consider. Getting treatment can not only get pricey, but it can also thin out resources. There&#8217;s also the question of availability. In China,<span style="font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen-Sans, Ubuntu, Cantarell, 'Helvetica Neue', sans-serif"> property giant Evergrande is about $300 billion in debt, and the deadline to address that debt has come and gone. Is it possible that a bailout could be in the works? There&#8217;s been plenty of regulation in store for food delivery apps focused on worker protections, but there are questions about how the app companies might change under this climate. </span></p>